Frequency and types of <i>EGFR</i> mutations in Moroccan patients with non–small cell lung cancer

Sow, Mohamed Lemine; Yacoubi, Hind El; Moukafih, Badreddine; Balde, S; Akimana, Gloria; Najem, S.; Khoyaali, Siham; Abahssain, Halima; Chaibi, Aicha; Khan, Shah Zeb; Trapani, Dario; Benzekri, Asmae; Ghaouti, Merieme; Gamra, L.; Mestari, Amina; Kettani, Fouad; Rahali, Younes; Mrabti, Hind; Elghissassi, Ibrahim; Errihani, Hassan

doi:10.1177/0300891620964571

Cited by 10 publications

(15 citation statements)

References 24 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the “classic” mutations such as deletion in exon 19 and p.L858R, we found that 23.5% of our patients carried deletion in exon 19, which is in line with data from previous studies including those conducted on Tunisian patients [ 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 ]. However, the p.L858R was identified in only four patients (11.7%), confirming once again the particularity of our cohort.…”

Section: Discussionsupporting

confidence: 91%

“…A meta-analysis including Middle Eastern and African studies reported a prevalence of 21.2% of EGFR mutations, varying from 44% in Turkey to 21% in Morocco and 2.1% in Saudi Arabia [ 34 ]. In addition, two recent studies from Morocco and Algeria revealed EGFR mutation frequencies of 21.9%, and 39.6%, respectively [ 35 , 36 ]. Analysis of the EGFR TKI sensitivity mutations in Tunisian NSCLC patients showed variable frequencies, depending on the number of analyzed samples, the patient’s selection criteria (clinical and pathological), and the used mutational analysis technique.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma

Abdelmaksoud‐Dammak

Ammous-Boukhris

Saadallah-Kallel

et al. 2022

Genes

View full text Add to dashboard Cite

Objectives: Several new cancer therapies targeting signaling pathways involved in the growth and progression of cancer cells were developed as personalized medicine. Our study aimed to identify epidermal growth factor receptor (EGFR) mutations for TKI treatment in non-small-cell lung cancer (NSCLC) Tunisian patients. Methods: Analysis of the TKI sensitivity mutations in exons 18 to 21 of the EGFR gene and exon 15 of the B-raf gene was performed in 79 formalin fixed-paraffin embedded (FFPE) NSCLC samples using pyrosequencing. Results: EGFR mutations were detected in 34 cases among 79 (43%), with the predominance of the L861Q in exon 21 found in 35.3% of the cases (12 out of 34). Deletions in exon 19 were found in 8 cases (23.5%), and only one young male patient had the T790M mutation. Three patients harbored composite EGFR mutations (p.E746_A750del/p.L861R, p.E746_S752>V/p.S768I, and p.G719A/p.L861Q). Furthermore, the EGFR mutated status was significantly more frequent in female patients (p = 0.019), in non-smoker patients (p = 0.008), and in patients with metastasis (p = 0.044). Moreover, the B-raf V600E was identified in 5 EGFR negative patients among 39 analyzed samples (13.15%). Conclusion: The p.L861Q localized in exon 21 of the EGFR gene was the most common mutation identified in our patients (35.3%), whereas the “classic” EGFR mutations such as Del19 and p.L858R were found in 23.5% and 11.7% of the cases, respectively. Interestingly, most of p.L861X mutation-carrying patients showed good response to TKI treatment. Altogether, our findings suggest a particular distribution of the EGFR-TKIs sensitivity mutations in Tunisian NSCLC patients.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma

Abdelmaksoud‐Dammak

Ammous-Boukhris

Saadallah-Kallel

et al. 2022

Genes

View full text Add to dashboard Cite

show abstract

“…The use of erlotinib or other tyrosine kinase inhibitors in advanced non-small cell lung cancer is recommended for EGFR-mutated subtypes(10), and is associated with improved survival. The rate of EGFR testing was 8.1% which remains low as compared to reports from other parts of Africa 13 , 14 . Despite the available evidence that EGFR TKI agents are associated with improved survival and quality of life among patients with EGFR-mutated NSCLC, access and cost of these medicines remain a key bottleneck.…”

Section: Discussioncontrasting

confidence: 61%

Clinical profile and initial treatment of non-small cell lung cancer: a retrospective cohort study at the Uganda Cancer Institute

Kibudde¹,

Kirenga²,

Nabwana³

et al. 2021

Afr H. Sci.

View full text Add to dashboard Cite

Introduction: Lung cancer is a major global public health burden constituting 11.6% of all new cancer diagnoses and 18.4% of all cancer-related mortality. Purpose: To describe the clinical profile and initial treatment of non-small cell lung cancer in Uganda. Methods: We reviewed charts of a cohort of patients with a histologically confirmed diagnosis of non-small cell lung cancer, treated between January 2013 and November 2015 at the Uganda Cancer Institute. Results: A total of 74 patients met the inclusion criteria. The median age was 56 years (IQR 47-70), with 16.2% below the age 45 years, and 51% were female. Only 10 percent were active smokers and the most frequent histological subtype was adenocarcinoma (71%). The majority (91.9%) had stage IV disease at diagnosis and frequent metastases to contralateral lung, liver, and bones. Twenty-seven (27) patients received platinum-based chemotherapy, while 27 patients received erlotinib, and only 4 patients received palliative thoracic radiotherapy. The median survival time was 12.4 months, and the overall response rate was 32.7%. There was no survival difference by type of systemic treatment, and on multivariate analysis, poor performance status was predictive of adverse outcomes (p < 0.001). Conclusions: Patients with non-small cell lung cancer in Uganda frequently presented with late-stage disease at diagnosis. The majority of patients were female, never-smokers, and had predominantly adenocarcinoma subtype. Keywords: Non-small cell lung cancer; Uganda; erlotinib; lung cancer; Uganda Cancer Institute.

show abstract

“…In Morocco, EGFR mutation prevalences ranged from 15.9% to 26.8%. 27 - 29 Details of EGFR mutation prevalences in the MENA region are summarized in Table 2 .…”

Section: Resultsmentioning

confidence: 99%

“…These articles were assessed for eligibility and 15 studies were selected for this review: 11 (73.3%) from the Middle East [16][17][18][19][20][21][22][23][24][25][26] and 4 (26.6%) in North Africa. [27][28][29][30] Original articles were identified from Jordan, 16 Iran, 17 Turkey, [18][19][20] Iraq, 22 Lebanon, [23][24][25] Morocco, [27][28][29] and Egypt. 30 A multicenter prospective study from the Levant (Lebanone, Syria, Palestine, Jordan, Iraq, and Egypt) 26 and a multisite retrospective study from the Gulf (Saudi Arabia, the United Arab Emirates and Qatar) were also identified and will be part of our analysis.…”

Section: Literature Researchmentioning

confidence: 99%

Prevalence and Patterns of EGFR Mutations in Non-small Cell Lung Cancer in the Middle East and North Africa

et al. 2022

View full text Add to dashboard Cite

Objectives This study aims to analyze the prevalence and spectrum of epidermal growth factor receptor (EGFR) mutations within the Middle East and North Africa region, compare the findings to other parts of the world, and explore the geographic disparities of EGFR mutations across the region. Methods We conducted a literature search using the terms “[EGFR] AND [mutation] AND [Non-Small Cell Lung Cancer] AND [Middle East OR North Africa]”, using PubMed, Science Direct, Web of science, Embase, Scopus, and Google scholar. Results A total of 15 eligible studies were included and 6122 patients with non-small cell lung cancer (NSCLC) were analyzed. Male patients were predominant in all of the considered studies, accounting for 70.4%. Of the included patients, 65.6% were smokers and 88.3% had been diagnosed with adenocarcinoma. Overall, EGFR mutations prevalence was 17.2%. In the Middle East, the reported frequency was 16.5%, ranging from 11.3% in Lebanon to 29.7% in the Gulf region. In North Africa, the prevalence of EGFR mutations was 18%, ranging from 17.5% in Egypt to 21.5% in Morocco. The most prevalent mutations were the exon 19 deletions (46.7%) followed by exon 21 substitutions (31.1%). Exon 20 alterations were detected in 10.8% of the analyzed cases, whereas exon 18 mutations were reported in 3.4% of the EGFR-mutated patients. There was 1.1% of patients that had concurrent EGFR mutations. Overall, EGFR mutation prevalence was higher in females [females vs males: 29.7% vs 5.9%, P<.001], non-smokers [non-smokers vs smokers: 31.3% vs 9.6%, P<.001], and patients with adenocarcinoma [adenocarcinoma vs non-adenocarcinoma: 18.8% vs 6.5%, P<.001]. Conclusion EGFR mutation prevalence among the Middle East and North Africa populations is slightly higher than that seen in NSCLC patients of Caucasian ethnicity but is lower than that identified in Asian NSCLC patients. The distribution of these mutations varies considerably throughout the region.

show abstract

Frequency and types of EGFR mutations in Moroccan patients with non–small cell lung cancer

Cited by 10 publications

References 24 publications

Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma

Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma

Clinical profile and initial treatment of non-small cell lung cancer: a retrospective cohort study at the Uganda Cancer Institute

Prevalence and Patterns of EGFR Mutations in Non-small Cell Lung Cancer in the Middle East and North Africa

Contact Info

Product

Resources

About